Molina Healthcare Cash & Equivalents Growth & History (MOH)
Molina Healthcare's cash and equivalents was $4.25B for fiscal 2025.
View full Molina Healthcare company overviewMolina Healthcare annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.25B | −$414.0M | −8.88% |
| 2024 | 2024-12-31 | $4.66B | −$186.0M | −3.84% |
| 2023 | 2023-12-31 | $4.85B | $842.0M | +21.02% |
| 2022 | 2022-12-31 | $4.01B | −$432.0M | −9.73% |
| 2021 | 2021-12-31 | $4.44B | $284.0M | +6.84% |
| 2020 | 2020-12-31 | $4.15B | $1.70B | +69.41% |
| 2019 | 2019-12-31 | $2.45B | −$374.0M | −13.23% |
| 2018 | 2018-12-31 | $2.83B | −$360.0M | −11.30% |
| 2017 | 2017-12-31 | $3.19B | $367.0M | +13.02% |
| 2016 | 2016-12-31 | $2.82B | $490.0M | +21.04% |
| 2015 | 2015-12-31 | $2.33B | $790.0M | +51.33% |
| 2014 | 2014-12-31 | $1.54B | $603.0M | +64.42% |
| 2013 | 2013-12-31 | $936.0M | $140.0M | +17.59% |
| 2012 | 2012-12-31 | $796.0M | $302.2M | +61.19% |
| 2011 | 2011-12-31 | $493.8M | $37.9M | +8.32% |
| 2010 | 2010-12-31 | $455.9M | −$13.6M | −2.90% |
| 2009 | 2009-12-31 | $469.5M | — | — |
Molina Healthcare quarterly cash and equivalents
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.99B | $486.0M | +10.80% |
| Q1 2026 | 2026-03-31 | $5.31B | $458.0M | +9.43% |
| Q4 2025 | 2025-12-31 | $4.25B | −$414.0M | −8.88% |
| Q3 2025 | 2025-09-30 | $4.22B | −$511.0M | −10.80% |
| Q2 2025 | 2025-06-30 | $4.50B | $145.0M | +3.33% |
| Q1 2025 | 2025-03-31 | $4.86B | $343.0M | +7.60% |
| Q4 2024 | 2024-12-31 | $4.66B | −$186.0M | −3.84% |
| Q3 2024 | 2024-09-30 | $4.73B | −$833.0M | −14.97% |
| Q2 2024 | 2024-06-30 | $4.35B | −$556.0M | −11.32% |
| Q1 2024 | 2024-03-31 | $4.51B | −$41.0M | −0.90% |
| Q4 2023 | 2023-12-31 | $4.85B | $842.0M | +21.02% |
| Q3 2023 | 2023-09-30 | $5.57B | $1.32B | +31.19% |
| Q2 2023 | 2023-06-30 | $4.91B | $598.0M | +13.87% |
| Q1 2023 | 2023-03-31 | $4.55B | −$250.0M | −5.20% |
| Q4 2022 | 2022-12-31 | $4.01B | −$432.0M | −9.73% |
| Q3 2022 | 2022-09-30 | $4.24B | −$115.0M | −2.64% |
| Q2 2022 | 2022-06-30 | $4.31B | −$296.0M | −6.42% |
| Q1 2022 | 2022-03-31 | $4.80B | $373.0M | +8.42% |
| Q4 2021 | 2021-12-31 | $4.44B | $284.0M | +6.84% |
| Q3 2021 | 2021-09-30 | $4.36B | $1.16B | +36.33% |
| Q2 2021 | 2021-06-30 | $4.61B | $1.30B | +39.51% |
| Q1 2021 | 2021-03-31 | $4.43B | $2.07B | +87.36% |
| Q4 2020 | 2020-12-31 | $4.15B | $1.70B | +69.41% |
| Q3 2020 | 2020-09-30 | $3.20B | $517.0M | +19.30% |
| Q2 2020 | 2020-06-30 | $3.30B | $1.05B | +46.60% |
| Q1 2020 | 2020-03-31 | $2.37B | −$859.0M | −26.64% |
| Q4 2019 | 2019-12-31 | $2.45B | −$374.0M | −13.23% |
| Q3 2019 | 2019-09-30 | $2.68B | −$135.0M | −4.80% |
| Q2 2019 | 2019-06-30 | $2.25B | −$1.15B | −33.75% |
| Q1 2019 | 2019-03-31 | $3.22B | −$505.0M | −13.54% |
| Q4 2018 | 2018-12-31 | $2.83B | −$360.0M | −11.30% |
| Q3 2018 | 2018-09-30 | $2.81B | −$1.12B | −28.47% |
| Q2 2018 | 2018-06-30 | $3.40B | $422.0M | +14.17% |
| Q1 2018 | 2018-03-31 | $3.73B | $531.0M | +16.60% |
| Q4 2017 | 2017-12-31 | $3.19B | $367.0M | +13.02% |
| Q3 2017 | 2017-09-30 | $3.93B | $1.09B | +38.42% |
| Q2 2017 | 2017-06-30 | $2.98B | $634.0M | +27.04% |
| Q1 2017 | 2017-03-31 | $3.20B | $1.04B | +48.33% |
| Q4 2016 | 2016-12-31 | $2.82B | $490.0M | +21.04% |
| Q3 2016 | 2016-09-30 | $2.84B | $678.0M | +31.33% |
| Q2 2016 | 2016-06-30 | $2.35B | $331.0M | +16.43% |
| Q1 2016 | 2016-03-31 | $2.16B | $286.0M | +15.29% |
| Q4 2015 | 2015-12-31 | $2.33B | $790.0M | +51.33% |
| Q3 2015 | 2015-09-30 | $2.16B | $565.4M | +35.37% |
| Q2 2015 | 2015-06-30 | $2.01B | $986.6M | +96.04% |
| Q1 2015 | 2015-03-31 | $1.87B | $786.6M | +72.61% |
| Q4 2014 | 2014-12-31 | $1.54B | $603.0M | +64.42% |
| Q3 2014 | 2014-09-30 | $1.60B | $742.0M | +86.63% |
| Q2 2014 | 2014-06-30 | $1.03B | $284.7M | +38.33% |
| Q1 2014 | 2014-03-31 | $1.08B | −$86.1M | −7.37% |
| Q4 2013 | 2013-12-31 | $936.0M | $140.0M | +17.59% |
| Q3 2013 | 2013-09-30 | $856.6M | $141.1M | +19.72% |
| Q2 2013 | 2013-06-30 | $742.7M | $15.6M | +2.14% |
| Q1 2013 | 2013-03-31 | $1.17B | $651.8M | +125.90% |
| Q4 2012 | 2012-12-31 | $796.0M | $302.2M | +61.19% |
| Q3 2012 | 2012-09-30 | $715.5M | $228.0M | +46.77% |
| Q2 2012 | 2012-06-30 | $727.1M | $267.9M | +58.33% |
| Q1 2012 | 2012-03-31 | $517.7M | — | — |
| Q4 2011 | 2011-12-31 | $493.8M | $37.9M | +8.32% |
| Q3 2011 | 2011-09-30 | $487.5M | — | — |
| Q2 2011 | 2011-06-30 | $459.2M | — | — |
| Q4 2010 | 2010-12-31 | $455.9M | — | — |
Molina Healthcare cash and equivalents trends
Over the last five fiscal years, Molina Healthcare's cash and equivalents increased from $4.15B to $4.25B, a change of $94.0M. The latest reported quarter, Q2 2026, shows $4.99B.
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Molina Healthcare source filings ↗